Product Compliance And Certification For Wearable Medical Device In Australia
A wearable does not obtain a single “Australian certification”. A wrist sensor, adhesive patch or smart ring may face TGA medical-device obligations, ACMA radio/EMC rules, electrical-equipment rules for its power supply, consumer battery safeguards and privacy duties in parallel. Which layers apply depends on intended purpose, design, radio features, supply chain and actual data handling.
Use the following map to identify the questions and documents needed before commissioning tests, printing labels or making disease-related claims. It is a product route map, not an assessment of an unidentified model.
First classify the wearable and each claimed function
Start with what the manufacturer says the product does in the app, instructions, packaging, clinician dashboard, website and advertising. Under the Therapeutic Goods Act 1989, a disease-related diagnostic, monitoring, prediction or treatment purpose may bring the wearable or its software into medical-device regulation. Merely collecting heart-rate data does not, on its own, decide the outcome.
Under the TGA’s March 2026 wellness guidance, item 14B of the Excluded Goods Determination can cover qualifying non-invasive consumer software or software-and-hardware for general wellness. It is not a blanket “fitness” exemption: clinical use or claims about serious conditions can defeat it, and each function of multifunction software needs analysis.
Distinguish an excluded good from an exempt medical device. An excluded good is outside the TGA medical-device regime; an exemption may dispense with ARTG inclusion but leave other TGA obligations in place. Do not call both “TGA approval not needed” without recording the applicable provision.
Claim-to-route examples: the same sensor, different result
| Illustrative configuration | Primary classification question | Safe initial treatment |
|---|---|---|
| Wristband shows exercise heart rate and sleep trends | Only personal wellness, with no clinical or serious-disease claim? | Document the item 14B exclusion analysis, including every function; still check ACMA and consumer-product duties. |
| Same band warns a cardiac patient of a dangerous threshold | Does the warning manage risk from a serious condition? | Treat TGA medical-device applicability as likely; assess full system and relevant classification rules. |
| Patch streams ECG traces to a clinician for diagnosis | Is the trace/algorithm used in clinical assessment? | Medical-device route is likely; define the patch, app and interpretation functions, users and failure consequences. |
| Consumer watch plus a separate diagnostic algorithm | Is only software making the regulated medical claim? | TGA may require ARTG inclusion for SaMD even where a finished general-purpose consumer device/sensor does not need its own entry; validate sensor compatibility. |
Australia cross-regime matrix for a connected wearable
| Layer / trigger | Who handles it | Evidence or launch gate |
|---|---|---|
| TGA: clinical purpose or medical SaMD | Manufacturer establishes intended purpose, class and conformity; Australian sponsor seeks ARTG inclusion where required. | Essential Principles evidence, appropriate conformity documents and matching ARTG scope before supply, absent a specific exclusion/exemption. |
| ACMA: Bluetooth, Wi-Fi, cellular radio and applicable EMC | The Australian responsible supplier under the applicable equipment rules. | Determine technical standards, testing/documentation, supplier registration and RCM labelling where applicable; ARTG is not a substitute. |
| EESS / electrical safety: charger and mains accessories | Assess mains-powered adapters and accessories whether bundled with the wearable or marketed separately. | Check voltage, intended use and EESS scope for each item. An extra-low-voltage or exclusively medical device may be outside EESS; a mains adapter may still be in scope. |
| ACCC: button/coin batteries in or supplied with consumer goods | Manufacturer, importer and other suppliers in the chain. | Check mandatory safety, testing and warning rules even for non-removable or enclosed button/coin batteries, subject to product-specific exclusions. An ordinary rechargeable battery is not automatically a button/coin cell. |
| Privacy: identifiable health data via app/cloud | Entities subject to Australian privacy law. | Map collection, consent where required for sensitive information, third parties, hosting and security; applicability depends on the entity and processing. |
| Advertising and post-market: medical claims and incidents | Sponsor and manufacturer, alongside the advertiser. | Claims must track intended purpose and ARTG entry; maintain complaints, correction/recall and incident processes. |
EESS out-of-scope does not mean electrically unsafe equipment may be supplied: assess applicable essential safety criteria, including AS/NZS 3820 where relevant, even when EESS registration is unnecessary. For a button/coin cell, check the exact consumer-product scope and exceptions (such as qualifying professional equipment or certain ICT equipment with soldered-in cells); a sealed housing alone is not an exemption.
Australian medical-device class is a risk decision, not a watch category
Apply Australian medical-device classification rules to each medical function and the highest applicable rule to the relevant device; do not copy an EU or US class. Under TGA guidance, routine measurement of physiological signals may engage Rule 4.3 and Class IIa, whereas vital-process monitoring where variation could create immediate danger may be Class IIb. Software used to inform diagnosis/treatment has separate risk-dependent rules. These are examples, not automatic classes for all watches.
If the medical claim belongs only to a diagnostic phone app used with a finished generic smartwatch, delineate which component is the regulated device. A dedicated biosensor, algorithm, cloud processing and clinician portal cannot simply be assumed to share one or separate ARTG entries: determine intended purposes, manufacturer and “kind of device”. For general Australian medical-device filing mechanics, see the broader Australian medical-device route.
Evidence pack for the exact hardware–app–cloud configuration
Request a model-specific evidence dossier; a CE mark, FDA clearance or ISO certificate alone is not an Australian supply permission:
- Version-controlled intended-purpose and claims inventory for watch/patch, firmware, app, cloud service and clinician screen.
- Architecture and manufacturer/variant map; sensor and algorithm boundaries, radio bands, antenna, battery and charger SKUs.
- Australian classification rationale, relevant rules, exclusions or exemptions analysis, GMDN and proposed ARTG scope.
- Essential Principles gap assessment, risk file, usability, electrical/biocompatibility as relevant, and clinical performance evidence tied to use population.
- Signal-quality, sensor validation, false-alarm/false-reassurance and connectivity-loss tests for the stated clinical workflow.
- Software verification, cybersecurity threat model, supported OS/phone versions, cloud dependency, update and vulnerability controls.
- Conformity/overseas-authorisation documents where acceptable, Australian sponsor access agreement and declarations as required by class.
- ACMA radio/EMC record, accessory electrical-safety assessment, applicable coin-cell evidence, draft labels/IFU and Australian privacy data-flow review.
Standards such as ISO 13485 or IEC 60601 may help demonstrate a requirement when relevant; they are not an automatic substitute for the legislation, classification or TGA assessment. Select tests only after the intended purpose and exact configuration are frozen.
Labels, UDI and advertising: three separate release checks
Medical-device information must meet Essential Principle 13 and the applicable sponsor-identification rules. For a wearable, reconcile device/box/IFU/app screens, intended users, limitations, skin-contact or charging warnings and supported smartphone/software versions. Electronic instructions for use are not automatically permitted in place of all physical information.
For regulated medical devices supplied in Australia, required device information must be available in English, including the manufacturer’s identification; Australian sponsor name and address must also be available in the manner required by regulation 10.2. Confirm the physical device, packaging and accompanying documents meet the applicable placement rules.
UDI is a separate device-identifier program, not the ACMA Regulatory Compliance Mark. Australia began mandatory UDI on 1 July 2026 for Class IIb and III devices; the staged dates include Class IIa from 1 July 2027, subject to scope and transitional provisions. Check the TGA decision tool for the exact model, manufacture/labelling date and overseas certificate.
For an in-scope wearable incorporating software, UDI applies to the physical device; embedded software not supplied independently does not automatically receive a separate UDI. A separately supplied diagnostic SaMD may require its own UDI, and electronically supplied SaMD must present it in a readily accessible on-screen location. Check the relevant software version, packaging and AusUDID record requirements.
For an in-scope medical device incorporating software, the UDI carrier must follow the physical-device label and packaging rules. For in-scope standalone SaMD, document the system-level UDI-DI and the software version in its UDI production identifier; confirm the required on-screen display.
If ACMA labelling rules apply, complete the supplier evidence/registration and RCM steps independently. Marketing must not say “TGA approved” or “TGA registered” as an endorsement; describe an applicable ARTG entry accurately and keep claims within its intended purpose.
Who must act before the first Australian supply
Use this release sequence; steps may overlap, but each gate needs its own sign-off:
- Freeze every Australian-facing medical and wellness claim and the intended users; record exclusion arguments function by function.
- Decide the regulated product boundary and Australian risk class; identify other possible regimes per hardware variant.
- Appoint/confirm a qualifying Australian sponsor if ARTG inclusion is needed; agree technical-document access and vigilance responsibilities.
- Complete the applicable manufacturer-evidence/conformity route, class-dependent documents and ARTG inclusion before regulated supply unless an exception applies.
- Close ACMA/RCM, EESS/charger, coin-battery and applicable data/privacy assessments; reconcile all product and app labels.
- Check current UDI obligations, advertising copy and post-market controls; release the exact validated version, not an unreviewed software build.
The TGA sponsor is not necessarily the same legal person as the ACMA responsible supplier or the privacy-law entity. Put each name, evidence owner and escalation route in a written responsibility matrix before importing stock.
Updates and failure modes that reopen the assessment
A new atrial-fibrillation detector, clinician alert threshold, remote medication recommendation, supported sensor model or cloud algorithm can change intended purpose, classification or required evidence. Treat clinical software updates as regulatory change-control events, not ordinary app-store housekeeping. Recheck ARTG entry scope and whether notification, variation or a new application is needed.
Radio-module or antenna revisions can reopen ACMA testing and RCM records; a charger substitution can change electrical assessment. A medical TGA pathway does not erase these parallel responsibilities. Before approving the change, capture the new claims, risk impact, test delta, label delta and party responsible.
Official regulatory starting points
- TGA — Wearable medical devices
- TGA — Consumer wellness exclusion (2026)
- TGA — Classification of active and software devices
- TGA — ARTG inclusion process
- TGA — Essential safety and performance principles
- TGA — Manufacturer conformity evidence
- TGA — Medical-device labelling
- TGA — UDI decision tool
- ACMA — Five steps for suppliers
- EESS — Equipment outside scope
- ACCC — Button-cell battery standards
- OAIC — Rules on collection of personal data
- TGA — Advertising and official endorsement
- TGA — Medical-device cybersecurity
- TGA — Software exclusions versus exemptions
- TGA — UDI for software and wearable systems
Wearable-specific questions and answers
Can an exercise smartwatch be sold without ARTG inclusion?
Possibly. A qualifying consumer wellness wearable may be excluded, but the analysis covers all functions and promotional claims. Exclusion from TGA regulation does not waive ACMA, electrical or consumer safety duties.
Does a CE-marked ECG watch automatically qualify in Australia?
No. Australian class, intended purpose, conformity evidence, sponsor and ARTG inclusion must be assessed. Comparable overseas authorisation may support an Australian pathway, not replace it.
Does an ECG app need registration if it uses an ordinary consumer watch?
Potentially yes. TGA may regulate the diagnostic SaMD while not requiring a separate ARTG entry for the generic consumer sensor product. The app must be validated against compatible sensors and models.
Is an RCM needed when the wearable has an ARTG number?
Assess ACMA obligations independently for radio/EMC equipment; where the labelling rules apply, ARTG inclusion does not replace the RCM process. A mains charger may also require a separate electrical-safety assessment.
What changed for a high-risk wearable on 1 July 2026?
UDI became mandatory for in-scope Class IIb and III devices, subject to specific timing, existing-stock and certificate-transition provisions. Review the TGA UDI decision tool; do not infer compliance solely from an existing ARTG number.